Skip to main content

Advertisement

SpringerLink
Log in

Vogt–Koyanagi–Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up

  • Clinical Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To report a case of Vogt–Koyanagi–Harada (VKH) syndrome associated with cutaneous pigmented malignant melanoma (MM) and non-pigmented nodular metastasis after a 10-year recurrence-free interval.

Methods

Case report with long-term follow-up of 11 years. Ocular examinations included best-corrected visual acuity (ETDRS charts), fundus photography, fluorescein angiography, and computer-assisted perimetry. In addition, human leukocyte antigen (HLA) typing was performed.

Results

A 48-year-old white female patient developed VKH disease 5 years after she had undergone surgical treatment of a superficial spreading melanoma on her back in 1991. The first symptoms were diffuse alopecia followed by growth of non-pigmented hair after 8 months. In our clinic, she presented 18 months later with cells and opacification in the vitreous, a macular and optic disc edema and atrophy of the retinal pigment epithelium (RPE). The anterior segment showed endothelial precipitates of the cornea, and a progressive secondary cataract. Fluorescein angiography detected a bilateral edema of the macula and the optic disc, and focal leakage in the RPE level. During follow-up the patient developed more cutaneous signs, such as vitiligo-like depigmentation and poliosis. A non-pigmented lymph node MM metastasis was diagnosed after a 10-year disease-free interval. HLA typing was positive for HLA-A*01, HLA-A*24, HLA-B*08, HLA-B*39, HLA-DRB1*03, and HLADRB1*11.

Conclusion

Our findings suggest that the described ocular findings of VKH disease may represent a component of a syndrome consisting also of melanoma-associated hypopigmentation. Within the framework of current concepts of immunity in patients with MM and VKH , the long recurrence-free interval might support the hypothesis of an autoimmune or hypersensitivity process against melanocytes. The use of immunosuppressive therapy in the treatment of VKH and its potential influence on the development of metastatic disease should be carefully reconsidered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Alaez C, del Pilar Mora M, Arellanes L, et al (1999) Strong association of HLA class II sequences in Mexicans with Vogt–Koyanagi–Harada disease. Hum Immunol 60:875–882

    Article  CAS  PubMed  Google Scholar 

  2. Boyd SR, Young S, Lightman S (2001) Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol 46:209–233

    Article  CAS  PubMed  Google Scholar 

  3. Chang MA, Fournier G, Koh HK, Sober AJ, Nakagawa H, Fitzpatrick TB, Albert DM (1986) Ocular abnormalities associated with cutaneous melanoma and vitiligoloke leukoderma. Graefes Arch Clin Exp Ophthalmol 224:529–535

    CAS  PubMed  Google Scholar 

  4. Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole IC (2001) A symbiotic concept of autoimmunity and tumor immunity: lessons from vitiligo. Trends Immunol 22:130–136

    Article  CAS  PubMed  Google Scholar 

  5. Kim MH, Seong MC, Kwak NH, et al (2000) Association of HLA with Vogt–Koyanagi–Harada syndrome in Koreans. Am J Ophthalmol 129:173–177

    Article  CAS  PubMed  Google Scholar 

  6. Kuo IC, Rechdouni A, Rao NA, et al (2000) Subretinal fibrosis in patients with Vogt–Koyanagi–Harada disease. Ophthalmology 107:1721–1728

    PubMed  Google Scholar 

  7. Lertsumitkul S, Whitcup SM, Nussenblatt RB, Chan CC (1999) Subretinal fibrosis and choroidal neovascularization in Vogt–Koyanagi–Harada syndrome. Graefes Arch Clin Exp Ophthalmol 113:1039–1045

    Article  Google Scholar 

  8. Lubin JR, Ni C, Albert DM (1982) Clinicopathological study of the Vogt–Koyanagi–Harada syndrome. Int Ophthalmol Clin 22:141–156

    CAS  Google Scholar 

  9. Massi D, Borgognoni L, Franchi A, Martini L, Reali UM, Santucci M (2000) Thick cutaneous melanoma: a reappraisal of prognostoc factors. Melanoma Res 10:153–164

    CAS  PubMed  Google Scholar 

  10. Matsuda H (1970) Electron microscopic studies on Vogt–Koyanagi–Harada syndrome and sympathetic ophthalmia with special reference to the melanocyte. Nippon Ganka Gakkai Zasshi 74:1107–1112

    CAS  PubMed  Google Scholar 

  11. Moorthy RS, Inomata H, Rao NA (1995) Vogt–Koyanagi–Harada syndrome. Surv Ophthalmol 39:265–292

    CAS  PubMed  Google Scholar 

  12. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9:689–696

    CAS  PubMed  Google Scholar 

  13. Nussenblatt RB, Palestine AG, Whitcup SM, Craven L (1995) Vogt–Koyanagi–Harada syndrome. In: Uveitis: fundamental and clinical practice, 2nd edn. Mosby, St Louis

  14. Ohno S (1981) Immunological aspects of Behcet’s and Vogt–Koyanagi–Harada diseases. Trans Ophthalmol Soc UK 101:335–341

    PubMed  Google Scholar 

  15. Ohno S, Minakawa R, Matsuda H (1988) Clinical studies of Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol 32:334–343

    CAS  PubMed  Google Scholar 

  16. Penn I (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55:742–747

    CAS  PubMed  Google Scholar 

  17. Penn I (1996) Malignant melanoma in organ allograft recipients. Transplantation 61:274–278

    CAS  PubMed  Google Scholar 

  18. Rao NA (1997) Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye 11:213–216

    PubMed  Google Scholar 

  19. Rathinam SR, Namperumalsamy P, Nozik RA, Cunningham ET (1999) Vogt–Koyanagi–Harada syndrome after cutaneous injury. Ophthalmology 106:635–638

    Article  CAS  PubMed  Google Scholar 

  20. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arrellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M (2001) Revised diagnostic criteria for Vogt–Koyanagi–Harada disease: Report of an international committee on nomenclature. Am J Ophthalmol 131:647–652

    CAS  PubMed  Google Scholar 

  21. Read RW, Rechodouni A, Butani N, Johnston R, Labree LD, Smith RE, Rao NA (2001) Complications and prognostic factors in Vogt–Koyanagi–Harada disease. Am J Ophthalmol 131:599–606

    CAS  PubMed  Google Scholar 

  22. Rubsamen PE, Gass JD (1991) Vogt–Koyanagi–Harada syndrome. Clinical course, therapy and long-term visual outcome. Arch Ophthalmol 109:682–687

    Google Scholar 

  23. Sahin S, Rao B, Kopf AW, Lee E, Rigel DS, Nossa R (1997) Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer 80:1426–1431

    Article  CAS  PubMed  Google Scholar 

  24. Sakamoto T, Murata T, Inomata H (1991) Class II major histocompatibility complex on melanocytes of Vogt–Koyanagi–Harada disease. Arch Ophthalmol 109:1270–1274

    CAS  PubMed  Google Scholar 

  25. Sober AJ, Haynes HA (1978) Uveitis, poliosis, hypomelanosis, and alopecia in a patient with malignant melanoma. Arch Dermatol 114:439–441

    Article  CAS  PubMed  Google Scholar 

  26. Sonoda S, Nakao K, Ohba N (1999) Extensive chorioretinal atrophy in Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol 43:113–119

    Article  CAS  PubMed  Google Scholar 

  27. Sugiura S (1978) Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol 22:9-35

    Google Scholar 

  28. Zetterstein E, Sagebiel RW, Miller JR, Tallapureddy S, Leong SPL, Kashani-Sabet M (2002) Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer 95:1049–1056

    Article  Google Scholar 

  29. Zhao M, Jiang Y, Abrahams IW (1991) Association of HLA antigens with Vogt–Koyanagi–Harada syndrome in a Han Chinese population. Arch Ophthalmol 109:368–370

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Ophthalmology, University of Cologne, Joseph-Stelzmann-Strasse 9, 50931 , Cologne, Germany

    Sabine Aisenbrey, Christoph Lüke, Helen D. Ayertey & Richard Brunner

  2. Department I, University Eye Clinic Tübingen, Tübingen, Germany

    Salvatore Grisanti

  3. Department of Internal Medicine II, University of Cologne, Cologne, Germany

    Andreas Perniok

Authors
  1. Sabine Aisenbrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Lüke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helen D. Ayertey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Salvatore Grisanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andreas Perniok
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard Brunner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabine Aisenbrey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aisenbrey, S., Lüke, C., Ayertey, H.D. et al. Vogt–Koyanagi–Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up. Graefe's Arch Clin Exp Ophthalmol 241, 996–999 (2003). https://doi.org/10.1007/s00417-003-0787-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-003-0787-5

Keywords

Search

Navigation